PanGen Biotech Inc. (KOSDAQ:222110)

PanGen Biotech Revenue

PanGen Biotech had revenue of 3.96B KRW in the quarter ending June 30, 2026, with 13.49% growth. This brings the company's total for the last twelve months to 14.18B, down -10.59% year-over-year. In the year 2025, PanGen Biotech had annual revenue of 13.42B, down -8.56%. That makes PanGen Biotech the 37,185th largest company in the world by revenue and 2,364th in South Korea.

• Revenue (ttm): 14.18B
• Revenue Growth: -10.59%
• P/S Ratio: 3.82
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 52.57B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Contract Manufacturing Organization (CMO) 5.65B 38.5%
• EPO Medicine 5.64B 38.5%
• Other 1.61B 11.0%
• Royalty 1.15B 7.8%
• Technology Transfer (CDO) 623.13M 4.2%

By Geography

• South Korea 8.87B 60.4%
• Overseas 5.81B 39.6%

Fiscal year ended Dec 31, 2024 See the full PanGen Biotech breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	13.42B	-1.26B	-8.56%
Dec 31, 2024	14.67B	7.36B	100.58%
Dec 31, 2023	7.32B	814.47M	12.53%
Dec 31, 2022	6.50B	-1.43B	-18.08%
Dec 31, 2021	7.94B	1.74B	28.18%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error